The peptide story

1921 - Toronto. Insulin.

The first peptide drug.

Frederick Banting was a 29-year-old surgeon with a failing practice. He had an idea about the pancreas - something it secreted was missing in diabetics, and you could pull that something out of an animal pancreas and inject it. He convinced a University of Toronto professor to give him a lab and an assistant for the summer. The assistant was a 21-year-old medical student named Charles Best.

By January 1922 they were injecting their extract into a 14-year-old diabetic boy in Toronto General Hospital. The boy weighed 65 pounds, was hours from death, and had been kept alive on a starvation diet of 450 calories a day. Within a week he was eating, walking, and gaining weight. He lived another 13 years.

That extract was insulin: 51 amino acids, the first peptide ever isolated from one mammal and used to save the life of another. Banting and the lab director won the Nobel Prize the next year. Banting split his prize money with Best.

The lesson the field absorbed: peptides aren't lab curiosities. They're how the body talks to itself. If you can copy a peptide your body makes, you can replace what's missing.

1981 - Bethesda. The thymus fragment.

NIH researchers were studying the thymus gland - a small organ behind your sternum that does immune system training during childhood and then mostly shrivels up by middle age. They isolated a protein the thymus secreted called Thymosin Beta-4, then identified the active fragment - a 17-amino-acid sequence later called TB-500.

What it did in animals was remarkable: it accelerated wound healing, repaired heart tissue after damage, helped tendons regenerate. Veterinarians started using it on race horses with leg injuries. Athletes heard about it. The horses got banned from major races.

TB-500 stayed semi-underground for forty years - too useful to ignore, too unstudied in humans for FDA approval, too easy to manufacture for any single company to bother with full clinical trials. It became the second half of the "Wolverine blend" stack with BPC-157 in modern recovery protocols.

The lesson: the thymus example showed that fragments of larger proteins could be drugs in their own right. You don't need the whole molecule. You need the part that fits the lock.

1991 - Croatia. The stomach lining peptide.

A Croatian gastroenterologist named Predrag Sikiric was studying gastric juice in the late 1980s. He noticed something his peers had ignored: when you damaged the stomach lining of a rat, the lining repaired itself with unusual speed. Something in the gastric juice was driving repair.

He spent a decade isolating it. The result: a 15-amino-acid peptide he named Body Protection Compound 157 - BPC-157 - because it appeared to protect every tissue type the rats had. Tendon. Ligament. Muscle. Brain. Skin. Gut, of course.

Sikiric and his lab kept publishing. Hundreds of animal papers across two decades. The mechanism appeared to be new blood-vessel growth in damaged tissue - the peptide was telling injured cells to recruit fresh blood supply.

Human clinical trials never materialized at scale. Croatian academic medicine doesn't have the funding pipeline of US pharma. But athletes started reading the papers. Then surgeons. Then sports-medicine doctors. By 2018, BPC-157 was the most-discussed recovery peptide on the internet, despite never being FDA-approved for any use.

The lesson: the gap between "real animal evidence" and "FDA-approved human drug" is massive, and it's not because the science is bad. It's because the funding model for translating science into approved drugs is broken for any molecule that's already off-patent or hard to patent.

1990s - The Bronx. The Gila monster.

This one is the best story.

John Eng was an endocrinologist at the Bronx VA Medical Center in the early 1990s. He was studying Gila monsters - venomous lizards from the American Southwest. Gila monsters eat maybe four times a year, gorge themselves, then go months without food. Their pancreas had to be doing something interesting to manage that.

Eng isolated a peptide from Gila monster venom that he named exendin-4. It mimicked GLP-1, a hormone the human gut releases after a meal that tells your pancreas to release insulin and tells your brain you're full. Native human GLP-1 had a half-life of two minutes - useless as a drug. Exendin-4 had a half-life of hours. Same signal, dramatically more durable.

Eng patented it. The VA didn't want it. He licensed it to a small biotech. That biotech got bought by a bigger biotech. The bigger biotech got bought by Eli Lilly. The drug, eventually, became Byetta. Then Trulicity. Then the field exploded.

By the late 2000s, Novo Nordisk had engineered their own long-acting GLP-1 - semaglutide. They added a fatty acid tail that let it bind to albumin, extending the half-life from minutes to a full week. They called it Ozempic.

The lesson: the most important peptide drug of the 21st century came from a desert lizard at a Bronx VA hospital. The next one is probably already in some weird animal nobody's looked at yet.

2017-2024 - Indianapolis. The cultural break.

Ozempic was approved for Type 2 diabetes in December 2017.

It wasn't a story for years. Diabetes drugs rarely are. But doctors started noticing diabetic patients losing dramatic amounts of weight - 15%, 20% of body weight in some cases. Off-label prescribing for obesity began quietly.

Eli Lilly was watching. They had their own GLP-1 in trials, plus a second receptor target called GIP. They combined them into a single molecule: tirzepatide. By 2022 they had a drug branded Mounjaro that was outperforming Ozempic in head-to-head weight loss data. By 2023 it was Zepbound, FDA-approved for obesity.

Then the cultural moment hit. Hollywood discovered it. Wall Street discovered it. Twitter discovered it. By 2024, "Ozempic face" was in headlines, "Are you on it?" was a polite question at parties, and the word "peptide" entered casual vocabulary for the first time in a hundred years.

For a year, all anyone talked about was the GLP-1 class. But behind the cultural noise, dozens of other peptides moved up the regulatory pipeline. Retatrutide (a triple-agonist successor to tirzepatide) ran through Phase 2 with even more dramatic data. Compounding pharmacies started shipping semaglutide nationwide. Telehealth made peptide prescriptions accessible to anyone with $300 a month.

The lesson: when a peptide breaks through the cultural barrier, it changes what's possible for the entire class. After Ozempic, every doctor's office in America knows what a GLP-1 is. That changes who gets prescribed what next.

The next decade

Three forces are converging right now:

• Manufacturing cost. What used to cost millions to synthesize at scale now costs thousands. New peptides hit the market faster.
• Compounding pharmacies. The legal route from "interesting research peptide" to "your doctor can write you a prescription" got dramatically shorter post-Ozempic. Multiple peptides without traditional FDA approval are now accessible via compounding plus telehealth.
• Trial pipeline. Late-stage trials on klotho (longevity), MOTS-c (mitochondria), and dual/triple-agonists for everything from PCOS to NASH liver disease are running. Some will fail. The ones that succeed will define the next decade of metabolic medicine.

The Protocol One bet: this category is going from "weird" to "table stakes" the same way Lipitor went from new to ubiquitous in the early 2000s. Most of the molecules that matter haven't hit the cultural radar yet. That's the gap.

Where to go next

• What are peptides - foundation
• How they work - mechanism
• What's coming - the trial pipeline
• The Directory - 17 specific peptides reviewed
• The Tier List - which ones to take seriously

Subscribe to the dispatch

The weekly Protocol One dispatch covers what's moving in peptides, GLP-1s, and longevity protocols. Free. 5-min read.

-> Subscribe free